Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (182)
  • Open Access

    REVIEW

    Use of DNA methylation patterns for early detection and management of lung cancer: Are we there yet?

    MILICA KONTIC1,2,*, FILIP MARKOVIC1

    Oncology Research, Vol.33, No.4, pp. 781-793, 2025, DOI:10.32604/or.2024.057231 - 19 March 2025

    Abstract Detecting lung cancer early is crucial for improving survival rates, yet it remains a significant challenge due to many cases being diagnosed at advanced stages. This review aims to provide advances in epigenetics which have highlighted DNA methylation patterns as promising biomarkers for early detection, prognosis, and treatment response in lung cancer. Techniques like bisulfite conversion followed by PCR, digital droplet polymerase chain reaction, and next-generation sequencing are commonly used for detecting these methylation patterns, which occur early in the cancer development process and can be detected in non-invasive samples like blood and sputum. Key… More >

  • Open Access

    REVIEW

    The role of glutathione peroxidase 4 in the progression, drug resistance, and targeted therapy of non-small cell lung cancer

    JIAHENG WEI1, LIANGMING ZHU2,*

    Oncology Research, Vol.33, No.4, pp. 863-872, 2025, DOI:10.32604/or.2024.054201 - 19 March 2025

    Abstract Lung cancer is one of the main causes of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) being the most prevalent histological subtype of lung cancer. Glutathione peroxidase 4 (GPX4) is a crucial antioxidant enzyme that plays a role in regulating ferroptosis. It is also involved in a wide variety of biological processes, such as tumor cell growth invasion, migration, and resistance to drugs. This study comprehensively examined the role of GPX4 in NSCLC and investigated the clinical feasibility of targeting GPX4 for NSCLC treatment. We discovered that GPX4 influences the progression of NSCLC More >

  • Open Access

    ARTICLE

    A Nomogram for Predicting Survival for Patients with Brain Metastatic and EGFR Mutation Advanced Non-Small Cell Lung Cancer

    JIYUN PANG1,2,#, WEIGANG XIU1,#, YUEYUN CHEN4, WENJING LIAO1,2, QIN ZHANG3,*, HUASHAN SHI4,*

    Oncology Research, Vol.33, No.4, pp. 895-904, 2025, DOI:10.32604/or.2024.053363 - 19 March 2025

    Abstract Background: Non-small cell lung cancer (NSCLC) is often accompanied by brain metastasis (BM), and the prognosis of patients with BM is poor. This study assesses the prognostic impact of BM in NSCLC patients with epidermal growth factor receptor (EGFR) mutations. Methods: We retrospectively evaluated 692 advanced NSCLC patients with EGFR mutations treated with tyrosine kinase inhibitors (TKIs) at West China Hospital from 2015 to 2019. The overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), disease control rate (DCR), and clinical parameters of the BM and non-BM groups were compared. Univariable and multivariable… More >

  • Open Access

    ARTICLE

    Evaluating the efficacy and safety of Anlotinib in conjunction with stereotactic radiosurgery for small cell lung cancer patients with brain metastases

    LIZHI WANG1, HUILIN SUN2, GUIZHI YU1, ZEJING QU1, YING JI1, YANPING CUI1,*

    Oncology Research, Vol.33, No.4, pp. 885-894, 2025, DOI:10.32604/or.2024.051586 - 19 March 2025

    Abstract Background: Small cell lung cancer (SCLC) is characterized by its aggressive nature and high propensity for brain metastases. This study investigates the clinical efficacy and safety profile of Anlotinib in combination with Stereotactic Radiotherapy (SRT) for treating brain metastases in patients with small cell lung cancer (SCLC). Methods: This research included 98 SCLC brain metastasis patients treated at Chengde Central Hospital from October 2020 to January 2024. The patients were categorized into a combined treatment group (CTG) (n = 45) and a Simple SRT group (SSG)(n = 53). The CTG (58 lesions) received Anlotinib with… More >

  • Open Access

    RETRACTION

    Retraction: miR-641 functions as a tumor suppressor by targeting MDM2 in human lung cancer

    Oncology Research Editorial Office

    Oncology Research, Vol.33, No.3, pp. 737-737, 2025, DOI:10.32604/or.2024.056910 - 28 February 2025

    Abstract This article has no abstract. More >

  • Open Access

    RETRACTION

    Retraction: miR-135a confers resistance to gefitinib in non-small cell lung cancer cells by upregulation of RAC1

    Oncology Research Editorial Office

    Oncology Research, Vol.33, No.3, pp. 733-733, 2025, DOI:10.32604/or.2024.056906 - 28 February 2025

    Abstract This article has no abstract. More >

  • Open Access

    ARTICLE

    Loss of TNFRSF21 induces cisplatin sensitivity in lung adenocarcinoma

    DAIEN ZHOU1,#, HAOYANG YUAN2,#, YIWEI HU3, CHUXU WANG1, SA GE1, KOUFENG SHAO4, HONGYING WANG1, XIAOFENG TIAN1,*, HAIBO HU1,*

    Oncology Research, Vol.33, No.3, pp. 653-663, 2025, DOI:10.32604/or.2024.050182 - 28 February 2025

    Abstract Background: Despite the identification of numerous therapeutic targets in lung cancer, achieving significant efficacy has been challenging. TNFRSF21 plays an important role in various cancers. We investigated the function of TNFRSF21 in lung adenocarcinoma (LUAD). Methods: The prognostic value of TNFRSF21 expression in lung cancer was evaluated by the GEPIA and Kaplan-Meier Plotter databases. Lung cancer cell viability was assessed by the CCK8 assay. TNFRSF21 expression patterns in lung cancer tissues and cells were examined using RT-PCR assay. Tumor sphere growth was evaluated through tumor sphere formation assays. MtROS contents in lung cancer cells were… More >

  • Open Access

    ARTICLE

    CAF-derived exosome-miR-3124-5p promotes malignant biological processes in NSCLC via the TOLLIP/TLR4-MyD88-NF-κB pathway

    TAO SUN1,2, QINGHUA SONG3, HUA LIU1,*

    Oncology Research, Vol.33, No.1, pp. 133-148, 2025, DOI:10.32604/or.2024.054141 - 20 December 2024

    Abstract Background: Lung cancer is a life-threatening disease that occurs worldwide, but is especially common in China. The crucial role of the tumour microenvironment (TME) in non-small cell lung cancer (NSCLC) has attracted recent attention. Cancer-associated fibroblasts (CAFs) are the main factors that contribute to the TME function, and CAF exosomes are closely linked to NSCLC. Methods: The expression levels of miR-3124-5p and Toll-interacting protein (TOLLIP) were analysed by bioinformatics prediction combined with RT-qPCR/Western Blot detection. Fibroblasts were isolated and identified from clinical NSCLC tissues. Transmission electron microscopy and Western Blot were used to identify exosomes… More >

  • Open Access

    ARTICLE

    Genetic signatures of ERCC1 and ERCC2 expression, along with SNPs variants, unveil favorable prognosis in SCLC patients undergoing platinum-based chemotherapy

    ENRICO CALIMAN1,2, SARA FANCELLI1,2, FEDERICO SCOLARI3, ADRIANO PASQUI4, CLARA MANNESCHI4, DANIELE LAVACCHI1, FRANCESCA MAZZONI4, FRANCESCA GENSINI5, VALERIA PASINI6, CAMILLA EVA COMIN2,7, LUCA VOLTOLINI2,8, SERENA PILLOZZI1,2,*, LORENZO ANTONUZZO1,2,4

    Oncology Research, Vol.33, No.1, pp. 45-55, 2025, DOI:10.32604/or.2024.050161 - 20 December 2024

    Abstract Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients’ survival. Materials and Methods: We conducted a retrospective analysis of data from 38 patients with extensive disease (ED)-SCLC who underwent platinum-CT at the Clinical Oncology Unit, Careggi University Hospital, Florence (Italy), from 2015 to 2020. mRNA expression analysis and single nucleotide polymorphism (SNP) characterization of three NER pathway genes—namely ERCC1, ERCC2,… More >

  • Open Access

    ARTICLE

    Long noncoding RNA LINC01106 promotes lung adenocarcinoma progression via upregulation of autophagy

    GENGYUN SUN1,*, YIPING ZHENG1,2, JIANFENG CAI2, JIE GAO2, LIE DONG2, XIANGBIN ZHANG2, YINGHUI HUANG2,*

    Oncology Research, Vol.33, No.1, pp. 171-184, 2025, DOI:10.32604/or.2024.047626 - 20 December 2024

    Abstract Background: Long noncoding RNA, LINC01106 exhibits high expression in lung adenocarcinoma (LUAD) tumor tissues, but its functional role and regulatory mechanism in LUAD cells remain unclear. Methods: LINC01106 expression was analyzed in LUAD tissues and its functional impact on LUAD cells was assessed. LUAD cells were silenced with sh-LINC01106 and injected into nude mice to investigate tumor growth. The downstream transcription factors and molecular mechanism were determined using the Human transcription factor database (TFDB) database and Gene Expression Profiling Interactive Analysis (GEPIA) database. Additionally, the impact of linc01106 on autophagy was analyzed by determining the… More > Graphic Abstract

    Long noncoding RNA LINC01106 promotes lung adenocarcinoma progression via upregulation of autophagy

Displaying 21-30 on page 3 of 182. Per Page